Phase 1/2 showed preliminary results from a clinical trial showing that it was well tolerated and that even a single dose appeared to produce a strong immune response in about 800 participants.
The trial included two age groups: 18- to 55-year-olds and 65- and older, and looked at the safety and side effects of two different doses. Preliminary findings from tests indicate that the vaccine stimulates immunity and that it is safe to go on a large scale test.
The study was posted on Medrexive, but has not yet been peer-reviewed or published in a medical journal.
The researchers found that 99% of participants between the ages of 18 and 55 in both dose groups developed antibodies against the virus 29 days after vaccination. The analysis found that most of the side effects, such as fever, headache, fatigue, body aches and injection-site pain, were alleviated and resolved after a few days.
Some participants will receive a second shot of the vaccine as part of the trial.
The vaccine known as Ad26.COV2.S – Johnson & Johnson uses the same technology used for the Ebola, Zika, HIV and RSV vaccines.
Phase 3 trials will test a measure of safety and effectiveness against placebo to prevent symptomatic covid-19. Johnson and Johnson say it’s a U.S. And plans to enroll 60,000 adult volunteers at more than 200 sites internationally.
Johnson and Johnson’s chief scientific officer, Dr. According to Paul Stofels, this trial will test the effectiveness of a single dose of the vaccine, rather than two doses, the results should be accelerated.
So far, it is the only Phase 3 Covid-19 vaccine test in the United States to test a single dose of the vaccine.
The company says U.S. Strict vaccine guidelines under consideration by the Food and Drug Administration may add to the company’s vaccine timeline.
Getting vaccinated
Meanwhile, the director of the National Institute of Allergy and Infectious Diseases, Dr. The Covid-19 vaccine could be launched in November or December, says Anthony Fauci.
But he warned that it could be the end of 2021 before things get back to normal.
“You’re going to vaccinate enough people until you realize you have had enough of an outbreak, so you might start thinking you might get a little bit more back to normal,” he said, probably like me and others. No. The third quarter or so will be. Maybe even in the fourth quarter, ”said Dr. A.S. Said in a conversation online with Howard Bouchner.
But he added that political interference is unlikely to play a role in the Kovid-19 vaccine approval process.
“If you look at the standard process of how these things work, I think you feel comfortable that this is not likely to happen.”
.
